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Abstract
Many neurotoxic substances produce toxic effects on the nervous system. 
Given the neurotoxic substances found in the human body, certain people have 
been regarded as having a propensity to epileptic seizures. In many situations, the 
neurotransmission processes of these toxins are similar to the physiopathology of 
epilepsy. Epileptic models have been developed to induce seizures in animals, allow-
ing researchers to study convulsive seizure mechanisms. Pentylenetetrazol, kainic 
acid, pilocarpine, penicillin, aluminum, bicuculline, picrotoxine, 4-aminopyridine, 
strictine, domoic acid, and other compounds fall under this category. However, 
there are some drugs used in clinical practice that can cause neurotoxicity as well. 
In this chapter, the predominant substances and drugs involved in epileptogenesis 
through neurotoxicity effects are reviewed. Throughout this chapter, we attempt to 
describe the mechanisms documented in the literature, in which epileptic seizures 
cause neurotoxicity in the brain by themselves, as shown with excitotoxicity medi-
ated by glutamate and ions involved.
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1. Introduction
The concept of toxicity refers to any substance capable of producing harm on 
livings organism. Hence, this chapter emphasizes on those compounds that harm 
the nervous system, particularly those capable of generating seizures. Within the 
pathophysiology of epilepsy, multiple mechanisms favor epileptogenesis, one of 
which is neurotoxicity. These excitotoxic mechanisms can exert their action through 
the glutamate receptors N-methyl-D-aspartate (NMDA); 𝜶-amino-2-3-dihydro-5-
methyl-3-oxo-4-isoxazolepropionic acid (AMPA) and kainate, opening ionic chan-
nels permeable to calcium (Ca2+), sodium ions (Na+), that participate significantly 
in the neuronal damage derived from the excitotoxic effects. Though there are 
spontaneous inducers of epilepsy, different models that replicate seizures have been 
created to better understand the mechanisms underlying epileptic seizures. These 
models promote neurotoxicity in the brain and are triggered by certain substances, 
primarily agonists or antagonists of neurotransmitters involved in epileptic activ-
ity. In this review we aim to illustrate the neurotoxic potency of numerous agents 
administered in the brain with neurotoxic qualities, including medications used in 
clinical practice that can generate neurotoxicity.
Epileptic seizures, according to the World Health Organization, are defined as a 
neurological, chronic, recurrent, and repetitive condition of paroxysmal phenomena 
caused by an excessive abnormal discharge of groups of neurons, which can occur 
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in different parts of the brain [1]. It is the result of synchronous electrical discharge 
from a group of hyper-excitable neurons, that when repeated consequently leads to 
neurotoxicity This hyperexcitability is due to an imbalance between the inhibitory 
processes given mainly by gamma-aminobutyric acid (GABA) and the excitatory 
ones of glutamate, which consequently modifies the function of ion channels 
regulated by Ca2+, Na+, and potassium (K+) mainly, which finally play a crucial 
role between the timing and propagation of abnormal discharges, contributing to 
the epileptic process [2]. Glutamate release activates NMDA ionotropic receptors, 
causing a rapid entry of Na+ and a slow entry of Ca2+. In epileptic seizures, with this 
massive entry of Ca2+, there is an increase of mitochondrial Ca2+ producing, among 
other effects an excitotoxic effect, in addition to free radicals production, proteases 
activation, and synthesis of nitric oxide which, by acting as a retrograde messenger, 
enhances the excitotoxic effect on the cell by also increasing glutamate release from 
the presynaptic terminals [3]. This glutamate release also activates the AMPA recep-
tors associated with non-voltage-dependent channels, responsible for depolarizing 
currents, due to the Na+ input. AMPA receptor antagonists are known to have been 
shown to markedly reduce or decrease epileptic activity [4].
Kainic acid (KA) glutamate agonist acts on glutamatergic receptors with a high 
affinity for KA which is associated with a Na+ ion channel, this depolarization 
in turn causes Na+ channels opening, which leads to Ca2+ channels aperture that 
further increases neuron excitability. Na+ channels’ participation in epileptogenesis 
and their mutations in many epileptic disorders has been long studied. The Na+ 
channels classified as type Nav 1.1 and Nav 1.6 are over-expressed in mice admin-
istered NMDA, which leads to hyperexcitability. However, when these animals are 
given phenytoin Na+ channel blocker, electrographic excitability decreases. Ion 
involvement has been described as vital in seizures [5]. The neurotoxic effect of 
KA appears to exert its action on non-NMDA receptors, located in the postsynaptic 
region at the dendrites of neurons level or by acting on presynaptic ionotropic 
glutamate receptors (NMDA, AMPA, and kainate) [6, 7]. Other glutamate receptors 
are also activated, predominantly found in the membrane of neurons, performing 
an excitatory response to the cell that presents them. When acting on the cell, there 
are even injuries to the cytoplasmic membrane, cytoplasmic vacuolization, and 
edema in the mitochondria, which finally cause cell death [8]. Kainate Glutamate 
stimulates postsynaptic AMPA receptors. This depolarization is immediately 
reduced by the GABA receptor recurrent inhibition [9].
Activation of AMPA receptors, particularly NMDA receptors, triggers intracel-
lular Ca2+ cascades. Ca2+ permeability studies indicate that there is also a low perme-
ability of this ion through kainate receptors [10, 11]. Excessive Ca2+ intake, derived 
from a pathological condition such as epilepsy, contributes to an excitotoxic effect 
and subsequent neuronal death [12].
In epileptic seizures, glutamate elevation and GABA release are observed from 
the presynaptic terminals within the synaptic cleft. Astrocytes recapture these 
abnormally released neurotransmitters during the seizure, protecting neurons from 
excitotoxicity and eliminating excess glutamate. It is known that, derived from the 
epileptic processes, there is hypertrophy and significant changes in the ramifica-
tions and volume of the astrocyte soma. These changes undoubtedly impact the 
reuptake of neurotransmitters such as glutamate, allowing an excess of this in the 
synaptic space [13, 14].
It is worth noting that epilepsy research is so broad that despite not managing to 
control the neuropathology, some authors have claimed that studying the disease 
has allowed neuroscience to investigate more than just seizure disorders, but the 
brain regions not directly implicated in epilepsy, as well. This chapter, however, will 




2. Calcium channels and epilepsy
When Ca2+ enters, it produces hyperexcitability in the excitable neuron through 
voltage-dependent Ca2+ channels (VDCCs). Intracellular processes are initiated 
when Ca2+ enters the cell, such as membrane excitability regulation, which permits 
neurotransmitters to be released. The biophysical and pharmacological proper-
ties of six types of Ca2+ channels (T, L, N, P, Q, and R) have been characterized. 
Low-threshold channels have been classed as T-type channels, while the rest have 
been classified as high-threshold channels. The number of depolarizations required 
for their activation has led to this classification. All channels have four subunits 
referred to as I through IV, each of which is made up of six transmembrane seg-
ments referred to as S1, S2, S3, S4, S5, and S6. The N, P and Q type channels are 
particularly crucial in controlling the release of neurotransmitters like glutamate 
and GABA, which, as previously stated, play a key role in epilepsy. The fact that a 
decrease in extracellular Ca2+ concentration can cause hyperexcitability in neurons 
is evidence that VDCCs play a major role in the epileptic activity [15]. In epilepsy, 
this correlates with paroxysmal depolarizations. Which correlates with paroxysmal 
depolarizations in epilepsy. This phenomenon has been observed in the hippocam-
pus’s neurons and dendrites, particularly in the CA1 and CA3 neuroanatomical, 
critical regions in epileptic seizures. Ca2+ currents have been demonstrated to pro-
mote the development of epileptic seizures; this is thought to be due to an increase 
in postsynaptic responses triggered by excessive excitement, which then initiates an 
epileptic seizure. However, this type of activity also leads to neuronal death.
Epileptic activity can also be triggered by the input of extracellular Ca2+ into the 
neuron, which promotes neuronal membrane depolarization and action potential 
production, resulting in abnormal discharges and seizures. The rise in intracellular 
Ca2+ in the postsynaptic neuron has been linked to various factors that produce 
epileptogenesis, including persistent depolarization, inducing neurotoxicity. Animal 
models in mice (tottering, du-du, or stargazer) in which genes coding for Ca2+ channel 
subunits formation have been altered and made it possible to illustrate the role of Ca2+ 
in epileptogenesis, implying that channelopathies may be part of the substrate for 
abnormal activity. Because Ca2+ plays such a role in abnormal epileptic activity, drugs 
like ethosuximide have been developed to block T-type Ca2+ channels by reducing Ca2+ 
entry. Hence, neurotransmitter release is implicated in neuronal excitability [16–19].
3. Molecular signaling pathways for epileptogenesis
This chapter proposes several molecular signaling pathways that are involved 
in epileptogenesis. We described the most representative pathways in the epi-
leptogenesis study. Until now, the complicated epileptogenesis pathophysiology 
and molecular processes that lead to seizures have remained a mystery. However, 
various anatomical pathways mechanisms, pathological pathways, and molecular 
interactions are known and have been explored based on the research available. 
Inhibitory and excitatory neurotransmission abnormalities have a big impact on 
neuron stability. Neuroinflammation and oxidative stress, for example, encourage 
the emergence of epileptic seizures and can potentially intensify them [20].
It has been claimed that the inflammatory state, and the elevation of its media-
tors, including IL-1ß, IL-6, high mobility group box TNF-α8, and cyclooxygenase-2. 
TNF-α produces endocytosis of GABA receptors through AMPA. Therefore, 
hyperexcitability in the hippocampus is boosted, resulting in seizures. Several 
studies have linked neuroinflammation to oxidative stress at the same time. The 
involvement of oxidative stress as a seizure generator is owing to an imbalance in 
Neurotoxicity - New Advances
4
the generation of reactive oxygen and nitrogen species, resulting in a deficiency in 
antioxidant mechanisms. The mitochondria are the body’s principal generator of 
oxygen radicals [21]. Other free radicals, including nicotinamide adenine dinucleo-
tide phosphate oxidase and xanthine oxidase, have been shown to act through 
glutamate receptors. The activation of the NMDA receptor is linked to epileptic 
activity [22].
Another pathway described in the study of epileptogenesis is the Wnt / 
β-Catenin pathway. Wnt/β-catenin is implicated in temporal lobe epilepsy. This 
pathway modulates, among other events, neuronal circuit formation and synaptic 
assemblages. Brain areas involved in epileptogenesis also play a key role in neuronal 
excitability modulation and neurotransmitter secretion. Wnt proteins dock with 
membrane receptors to initiate one of two major signal pathways: the canonical 
β-catenin pathway or the non-canonical pathway. β-catenin pathway manages 
transcriptional activity regulation and gene activation through the T-cell factor/
lymphoid enhancing factor pathway (TCF / LEF), that dictates cell determination, 
proliferation, and differentiation. Wnt1, Wnt3a, Wnt7a, and Wnt8 are most com-
monly found in β-catenin-dependent signaling. When one of these proteins binds 
to lipoprotein-related protein receptors, they lead to selective activation of the 
canonical pathway. Therefore, β-catenin dissociates from the degradation complex 
composed of axin, adenomatous polyposis coli protein (APC), casein kinase 1 
(CK1), and glycogen synthase kinase 3 β (GSK3β). This promotes the accumulation 
of β-catenin in the cytosol, which is then translocated to the nucleus and associated 
with transcription factors of the TCF/LEF family to regulate Wnt-dependent gene 
expression. In the absence of the Fzd receptor by Wnt, the Axin and APC proteins 
boost phosphorylation of β-catenin through the kinases CK1 and GSK3-β. These 
proteins promote the ubiquitination and subsequent degradation of β-catenin by 
the proteasome [23].
Notoginsenoside R1 (NGR1, was recently discovered to upregulate mRNA 
levels of the proteins β-catenin, Dvl, and Fzd, as well as promote the proliferation 
of cultured cortical neurons. NGR1 has also been discovered to reduce persistent 
K+ currents in hippocampus neurons, resulting in a reduced peak threshold. 
Treatment with a Wnt3a ligand, which activates the FZD receptor, caused K+ 
channel internalization and enhanced β-catenin expression, according to a recent 
study. GSK-3β inhibition caused by Wnt/β-catenin activation resulted in a lack of 
phosphorylation of GSK on the surface of K+ channels, resulting in internalization. 
This action lowers the current density of K+ channels, preventing them from acting 
as hyperexcitability regulators. The non-canonical route refers to pathways that do 
not rely on β-catenin-TCF/LEF and instead rely on alternative downstream effectors 
to produce a transcription response. The Wnt /PCP (planar cell polarity) pathway, 
via Wnt-cGMP/Ca2+, via Wnt/Via Ror, via Wnt-RYK, and via Wnt-mTOR are some 
of these pathways. Epileptogenesis has been linked to the mTOR signaling pathway. 
Wnt7a, a Wnt family ligand, is expressed in cerebellar granule cells and operates as 
a particular canonical signaling activator. Wnt7a is expressed in the developing hip-
pocampus as well, particularly in the dentate gyrus and CA1 regions, as indicated by 
an increase in active β-catenin immunofluorescence after recombinant Wnt7a was 
applied. Other studies have shown that Wnt7a has a role in synapse formation, with 
an increase in the number of vesicular glutamate transporters puncta per dendritic 
area after hippocampal neurons were treated with recombinant Wnt7a, resulting 
in an increase in excitatory neurotransmitter. Wnt8a is also involved in synaptic 
terminal excitability modulation. Additionally, it is also involved in the regulation 
of synaptic terminal excitability. These findings show that Wnt impacts synaptic 




ligand-gated ion channels in the postsynaptic membrane via canonical activation. 
These physiological changes on the synaptic terminal of hippocampus neurons may 
play a role in the temporal lobe epilepsy pathophysiological pathway. The aforemen-
tioned is attributed to synaptic transmission imbalances between inhibitory and 
excitatory synapses [24].
In a previous study, a significant increase in β-catenin signaling in the cerebellar 
cortex of rats after kindling-induced generalized seizures was observed. β-catenin 
activation induces apoptosis through the expression of cMyc upregulation, a protein 
that negatively regulates anti-apoptotic proteins such as Bcl-2. This leads to a loss of 
mitochondria, membrane potential, releasing cytochrome-c and promoting activa-
tion of caspases 3 and 9, leading to neuronal death. The Wnt/β-catenin pathway 
participates not only in neuronal synchrony regulation. But also in NMDA receptor 
modulation, which, as previously described, plays an important role not only in 
epilepsy but also in epileptogenesis [25, 26].
4. Toxic substances that cause seizures
Exposure to toxins can trigger seizures due to their damaging effect on the 
nervous system through different mechanisms (Table 1). The ability of organo-
phosphate insecticides to induce epileptic seizures is known through the inhibi-
tion of acetylcholinesterase due to its chemical structure that contain the groups 
carbamoyl and thiocarbamoyl, due to its capacity to phosphorylate and inactivate 
acetylcholinesterase and in addition to stimulating cholinergic receptors, these 
pesticides include parathion, chlorpyrifos, aldicarb, and carbaryl. Certain toxins 
present a dual mechanism for epileptic seizures production through the facilitation 
of the activation and the inhibition of voltage-gated Na+ channels, how is the case 
for chemical and biological warfare agents like sarin and soman, as well as toxins 
such as scorpion venom and ciguatoxin that can lead to seizures by modulating 
ion flow through Na+ channels. In other instance, anatoxin is a potent agent that 
causes seizures by the nicotinic receptor activation. The imbalance in inhibitory and 
excitatory neurotransmission is one of the mechanisms by which seizures occur. Par 
excellence GABA is the inhibitory neurotransmitter and glutamate is the excitatory 
neurotransmitter in the CNS, seizures are triggered by the activation of glutamate 
receptors by kainic acid and domoic acid, cyanide and azide both display the same 
process after cellular damage. Interference with the inhibition produced by GABA 
can trigger epileptic events, GABA receptor inhibition is caused by lindane, picro-
toxin, strychnine, and tetramethylenedisulfotetramine [27–29].
Toxic substance Mechanism
Parathion, chlorpyrifos, aldicarb, and 
carbaryl
Inhibiting acetylcholinesterase and hyperstimulation of 
cholinergic receptors
Sarin, soman, scorpion venom and 
ciguatoxin
Modulating ion flow through voltage-gated sodium channels
Anatoxin Nicotinic receptor activation
Kainic acid and domoic acid Activation of glutamate receptors
Lindane, picrotoxin and strychnine GABA receptor inhibition
Table 1. 
Toxic substances that can trigger seizures  and their exerting mechanism.
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5. Drugs associated with seizures
The administration of different drugs used therapeutically can predispose to 
epileptic seizures presence either by lowering the epileptogenic threshold, intoxica-
tion, or overdose of these. The main groups of antimicrobials that can cause seizures 
are beta-lactams, anti-tuberculous, and antimalarials. The pro epileptogenic effect 
of beta-lactams is related to high doses or their toxicity. Seizures related to drugs 
used to treat tuberculosis are mainly due to vitamin B6 deficiency. Mefloquine and 
chloroquine are reported antimalarial drugs that can lead to seizures. The procon-
vulsive effect of methylxanthines is thought to be due to A1 adenosine receptor 
inhibition. Paradoxically, it is known that carbamazepine can worsen generalized-
onset seizures. As well as the withdrawal effect of benzodiazepines, which in some 
cases can lower the seizure threshold [30–34]. Table 2 summarizes the main drugs 
associated with seizures. The following part reviews some of the toxic effects of the 
main antiepileptic drugs used in clinical practice.
5.1 Valproic acid
Since 1978, valproic acid or Na+ valproate has been characterized as an antiepilep-
tic drug that suppresses the neuronal excitation of different types of epilepsy, such 
as partial seizures and generalized seizures [35]. It appears that valproic acid exerts 
its inhibition by blocking the reuptake of the neurotransmitter GABA, the main 
inhibitory neurotransmitter. It also lowers glutamate levels and modifies K+ con-
ductance [36], exerting an inhibition through the voltage-dependent Na+ channels. 
In this way, it reduces the excitement caused by epileptic seizures [37]. Once this 
drug reaches the central nervous system (CNS), it binds to plasma proteins and is 
distributed throughout the extracellular space [38]. It is metabolized in the liver and 
discharged through the urine. Although it is also eliminated with expirations in the 
form of CO2 [39]. However, this drug is known to have frequent toxic effects derived 
from the therapeutic dose in patients with toxic plasma levels greater than 120 μg/
ml [40]. After an overdose, the patient may be lethargic and coma, most likely due 
Category Drugs associated with seizures
Sympathomimetics Phenylephrine, pseudoephedrine, and anorexiants
Analgesics Opioids
Anticancer drugs Interferon alfa, methotrexate, mitoxantrone, nelarabine, platinum-based, 
cisplatin, vinblastine, vincristine, busulfan, chlorambucil, cytarabine, 
doxorubicin, etoposide, and fluorouracil
Antimicrobials Carbapenems, cephalosporins, fluoroquinolones, isoniazid, and penicillin
Hypoglycemics Any antidiabetic that causes hypoglycemia
Immunosuppressants Cyclosporine, mycophenolate, tacrolimus, and azathioprine
Psychopharmaceuticals Monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, 
serotonin-norepinephrine reuptake inhibitors, serotonin modulators, 
tricyclic antidepressants, antipsychotics, atomoxetine, bupropion, 
buspirone, and lithium
Stimulants Amphetamines and methylphenidate
Xanthine Aminophylline and theophylline
Antiepileptics Carbamazepine and benzodiazepines
Table 2. 




to inhibition produced in the CNS [41]. Another adverse situation that derives from 
the consumption of this antiepileptic drug is cerebral edema, probably caused by the 
overstimulation of the stimulation of NMDA receptors [42]. Cardiovascular altera-
tions such as hypotension with tachycardia, gastric alterations such as pancreatitis, 
and hepatotoxicity have manifested with elevated transaminases, jaundice, and 
abdominal pain with inflammation, among others, may also occur [43].
5.2 Phenobarbital
Phenobarbital belongs to the family of barbiturates. These are characterized by 
providing the central nervous system with a depressant effect depending on the 
administered dose [44]. Its anticonvulsant mechanism is based on increasing the 
inhibitory activity of GABA, binding to the GABA receptor, and facilitating even 
more inhibitory neurotransmission. This inhibition reduces ATP levels, which 
causes the opening of Ca2+ channels associated with the NMDA receptor, coupled 
with the fact that a prolonged opening of these Ca2+ would lead to excitotoxic 
neuronal death [45]. The anticonvulsant dose ranges between 10 and 40 μg/
ml. The administration of these doses and higher ones generates toxicity that is 
generally due to the increase in Ca2+ entry into the neuron [46]. Mitochondria 
are an intracellular target of barbiturates since they depolarize the mitochondrial 
membrane by inhibiting complex one of the electron transports chains and, 
furthermore, they could have an uncoupling effect on oxidative phosphorylation 
[47]. Its absorption of phenobarbital is gastric, which generates a decrease in 
peristaltic tone. Although it is metabolized in the liver and discharged through 
the kidneys and urine, it has a great fat solubility that crosses cell membranes, 
producing several alterations [48].
5.3 Carbamazepine
Carbamazepine is a mainly antiepileptic psychotropic drug whose mechanism of 
action is based on reducing glutamate release, reducing the permeability of neuronal 
membranes to Na+ and K+ ions, stabilizing neuronal membranes, and depressing 
dopamine and norepinephrine turnover, though an inhibitory effect on muscarinic 
and nicotinic receptors is also known [49]. When its therapeutic plasma concentra-
tions are higher than 10 μg/ml, it produces toxic effects initially characterized by 
tachycardia, hypotension and hypertension, lethargy, ataxia, dysarthria, and nystag-
mus can occur, there are also gastric alterations such as vomiting and nausea. When 
intoxication is severe, it could even cause a coma [50]. Carbamazepine absorption 
is digestive, metabolized in the liver where it can cause liver dysfunction and, as its 
elimination is via the kidneys, adverse effects can also occur in this way [51].
5.4 Phenytoin
Phenytoin has been the most commonly used antiepileptic drug for patients 
with focal and generalized epilepsies since 1938 [52]. Its mechanism of action 
is exerted by inactivating voltage-gated Na+ channels. It also acts by inhibiting 
the flow of Ca2+ through neuronal membranes, such as it is to be expected at the 
cardiac level, it also inhibits Na+ channels, which is why it has toxic effects on the 
myocardium [53]. Phenytoin is bound to plasma proteins, such as albumin, which 
is metabolized in the liver, so it can cause liver diseases. Toxic effects are present 
even if the patient has adequate therapeutic levels, like at concentrations lower than 
20 mg/Kg [54, 55]. Among the clinical toxic effects, patients may present nystag-
mus, ataxia, and numbness [56]. With more severe intoxications, in addition to the 
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above: dysarthria, ataxia, the patient might not be able to walk, and may present 
hyperreflexia, besides consciousness usually being inhibited [57]. With higher 
doses, patients may even display a coma [58].
5.5 Lamotrigine
Lamotrigine is an antiepileptic drug principally used for generalized and partial 
seizures; it is also used in the adjunctive treatment of refractory crises [59]. Its 
action mechanism at the cellular level is based on blocking excitatory neurotrans-
mitters, especially glutamate, through its NMDA receptors, as well as inhibiting 
voltage-dependent Na+ currents [60]. The toxic effects on patients who take this 
drug above 600 mg are characterized primarily at the CNS level by difficulty in 
concentration, showing dysarthria, nystagmus, and blurred or double vision. 
Patients may even present a loss of balance or coordination [61]. Its absorption 
is intestinal, its elimination in the urine, metabolized in the liver. Thus, there is 
idiosyncratic hepatotoxicity that commonly requires liver transplantation [62].
5.6 Oxcarbazepine
Oxcarbazepine is a derivative of carbamazepine, approved as an antiepileptic 
drug in America in 2000 [63]. This drug is used in the treatment of any type of 
epileptic seizure. The cellular mechanism by which it exerts its antiepileptic effects 
is based on the fact that it blocks voltage-gated Na+ channels, modulates the activ-
ity of Ca2+ channels, and increases K+ conductance, which consequently produces 
a stabilization of hyperexcited neuronal membranes for epileptic seizures [64]. 
Oxcarbazepine is a drug that is metabolized like other antiepileptic drugs by the 
liver and excreted by the kidney [65]. Toxic effects when daily doses are above 
30 mg/kg are basically characterized by gastric alterations: mainly nausea and 
vomiting. The alterations in the CNS are identified by headache, fatigue, drowsi-
ness, and ataxia. It has also been reported that some patients may have vertigo and 
hyponatremia [66].
5.7 Ethosuximide
Ethosuximide is an anticonvulsant used to reduce the frequency of absence-type 
seizures. It exerts its mechanism by reducing Ca2+ currents antagonized by the T-type 
Ca2+ channels. Furthermore, linked to this drug, modulation of the function of volt-
age-activated Na+ channels and Na+/K+ dendritic hyperpolarization-activated cyclic 
nucleotide-gated channel 1 channels has been suggested. It also reduces neuronal 
excitability by inhibiting the Na+/K+ pump [67]. However, ethosuximide is almost 
entirely absorbed in the digestive tract and metabolized in the liver, which can cause 
liver disease. The toxic effects of patients who consume above 25 mg/kg comprise 
gastric issues, nausea, vomiting, constipation, a state of sedation, headache, 
decreased alertness, drowsiness, and even comas have been reported at the CNS level 
[68]. Other adverse effects may include weight loss, as well as leukopenia [69].
5.8 Gabapentin
Gabapentin acts mainly by inhibiting partial and generalized seizures. Its 
mechanism of action is based on enhancing the inhibitory action of GABA [70]. A 
dose above 1,500 mg of gabapentin can cause hepatotoxicity, additionally, coupling 
various toxic effects like headaches, diplopia, nystagmus, diplopia, even involun-





Topiramate is a drug used as an antiepileptic drug that acts by inhibiting partial 
and generalized seizures. Its action mechanism is exerted by blocking Na+ chan-
nels. As an AMPA receptor antagonist, it reduces excitatory neurotransmission, 
in addition to enhancing the inhibitory action of GABA [72]. Topiramate taken at 
a dose above 50 mg produces toxic effects, including dizziness. At the CNS level, 
patients have headaches, drowsiness, decreased concentration, and even confusion. 
Nevertheless, other anomalies have also been reported [73].
6. Experimental models of epilepsy and neurotoxicity
As noted, before the development of epilepsy, experimental models have been 
crucial in the further research of a neurological disorder affecting approximately 
1% of the worldwide population. Some drugs cause structural and metabolic altera-
tions in the nervous system as demonstrated by experimental epileptic models, 
culminating in seizure generation [74]. Antiepileptic drugs that are conventionally 
used in clinical practice have been successfully tested in many of these models, even 
though certain models have neurotoxic consequences, as we will discuss below.
With the aluminum model, focal seizures are studied by directly applying 
the substance to the cerebral cortex of the animal under study, where it has been 
observed that this substance generates dendritic loss, gliosis, loss of GABAergic 
neurons, and a decrease in glutamate decarboxylase [75, 76]. This model has been 
used to study antiepileptic drugs including diphenylhydantoin and pentobarbital, 
both of which have shown positive outcomes in reducing epileptic seizures fre-
quency [77].
Focal seizures have been researched using cobalt powder, which has been 
applied to the research animal’s cortex or thalamus for epileptogenesis as part of the 
model development. This has reported GABA and glutamate decarboxylase enzyme 
production decreased, whereas neuronal death has been observed in the hippocam-
pus. This cobalt model has also been suggested to interfere with Ca2+ signaling at 
NMDA glutamate receptors [78–80].
Similarly, using Zinc as an epilepsy model has been associated to neuronal 
death in the hippocampus, interference with GABAA receptors, and changes in the 
synapses of mossy fibers when there is a high concentration of this metal. It has 
also been observed to interfere with the responses of various receptors, including 
GABA, NMDA, and AMPA [81, 82]. While kainic acid, as an epileptic model, func-
tions similarly to glutamate. The hippocampus is the most sensitive structure to this 
agent, with the highest number of receptors reported in the CA3 layer. This epilepsy 
model is used to examine focal seizures, with the hippocampus being the most sen-
sitive structure to this substance. Changes in neuropeptide Y levels, hippocampus 
mossy fiber formation and a decrease in GABAB receptors are reported [83–85].
Pentylenetetrazol is used as an epileptic model to research generalized seizures. 
Shifts in the CA3 layer of the hippocampus, increased voltage in voltage-responsive 
K+ receptors, and interactions with GABAA and NMDA receptors have all been 
documented [86, 87]. The model has been shown to be suppressed by phenytoin 
and pentobarbital [88, 89]. Flurothyl gas, on the other hand, can cause status 
epilepticus in laboratory animals. Although this gas has long been utilized to inves-
tigate generalized seizures, the exact mechanism through which it causes seizures 
is yet uncertain. However, alterations in the lipidic membranes of hippocampus, 
amygdala, and cerebral cortex cells have been reported. A decrease in GABA 
synthesis and activation of the c-Fos gene have also been reported [90–92].
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On the other hand, penicillin, like cobalt, has been utilized as a model for focal 
seizures in epilepsy research, causing myoclonic seizures. The loss of GABAergic 
neurons, neuronal death, and an increase in mossy fibers in the hippocampus are 
the key abnormalities seen in this model [93–95]. While bicuculline is classified as a 
GABA antagonist, it causes generalized seizures when used. Edema has been found 
in the astrocytes of the cerebral cortex, where it interacts with Ca2+ and K+ channels 
[96, 97]. Tetanus toxin has also been employed as a model of epilepsy because of its 
effect on seizure induction. There are interactions with inhibitory neurotransmis-
sion, synapse formation, exocytosis blocking, and a decrease in GABAergic signal-
ing threshold with this substance [98, 99].
Additionally, pilocarpine affects the muscarinic acetylcholine receptors. The 
increase in activation of these receptors in the hippocampus characterizes its 
epileptogenic effect. In experimental animals, it can even cause status epilepticus. 
Significant damage to nervous system structures has been observed, particularly 
the entorhinal and piriform cortex, olfactory bulb, amygdala, hippocampus, and 
thalamus, as well as abnormalities in the function of Na+/K+ ATPase and NMDA 
receptors [100–103].
7. Conclusion
The described above has enabled us to identify the excitotoxic effect induced 
by epileptic seizures, whether clinical or experimental. Likewise, it illustrated 
some of the toxic effects of antiepileptic drugs. From what has been illustrated, it 
is necessary to conduct research that allows offering other therapeutic alternatives 
to reduce the toxic effects of seizures and pharmacological therapy. The proposal 
of alternative treatments to treat seizures is essential to boost anti-toxic defense 
mechanisms. It can be suggested to propose therapies that minimize neuronal death 
or treatments with substances that activate antiepileptic protein activity, such as the 
extrinsic and intrinsic Wnt pathway stimulation, or molecules that interact with the 
proteins involved in inflammatory and oxidative processes. The above mentioned 
could overall help reduce the interactions between the epileptic and pharmacologi-
cal processes that ulteriorly lead to toxic effects on epileptic patients.
Appendices and Nomenclature
NMDA  Glutamate receptors N-methyl-D-aspartate
AMPA  𝜶-amino-2-3-dihydro-5-methyl-3-oxo-4-isoxazolepropionic acid
GABA  Gamma-aminobutyric acid
Ca2+  Calcium
Na+  Sodium ions
K+  Potassium
CNS  Central nervous system
TCF/LEF T-cell factor / lymphoid enhancing factor pathway
APC  Adenomatous polyposis coli protein
CK1  Casein kinase 1
GSK3β  Glycogen synthase kinase 3 β
NGR1  Notoginsenoside R1





Carmen Rubio1, Artemio Rosiles-Abonce1, Elisa Taddei1 
and Moisés Rubio-Osornio2*
1 Department of Neurophysiology, National Institute of Neurology and 
Neurosurgery, Mexico
2 Department of Neurochemistry, National Institute of Neurology and 
Neurosurgery, Mexico
*Address all correspondence to: ruomon@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Neurotoxicity - New Advances
[1] Epilepsy [Internet]. [cited 2021 Aug 
21]. Available from: https://www.who.
int/news-room/fact-sheets/detail/
epilepsy
[2] An Introduction to Epilepsy 
[Internet] - PubMed [Internet]. [cited 
2021 Aug 21]. Available from: https://
pubmed.ncbi.nlm.nih.gov/20821849/
[3] Blanke ML, VanDongen AMJ. 
Activation Mechanisms of the NMDA 
Receptor. Biol NMDA Recept [Internet]. 
2009 Jan 1 [cited 2021 Aug 21];283-312. 
Available from: https://www.ncbi.nlm.
nih.gov/books/NBK5274/
[4] Boison D. New insights into the 
mechanisms of the ketogenic diet. 
Curr Opin Neurol [Internet]. 2017 Apr 
1 [cited 2021 Aug 21];30(2):187. 
Available from: /pmc/articles/
PMC5409832/
[5] J L, JM M. Kainate receptors in health 
and disease. Neuron [Internet]. 2013 
Oct 16 [cited 2021 Aug 21];80(2): 
292-311. Available from: https://
pubmed.ncbi.nlm.nih.gov/24139035/
[6] Garthwaite J, Garthwaite G. The 
mechanism of kainic acid neurotoxicity. 
Nat 1983 3055930 [Internet]. 1983 [cited 
2021 Aug 21];305(5930):138-40. 
Available from: https://www.nature.
com/articles/305138a0
[7] Y Y, J B, AJ B, ML M, AY L. 
Conformational analysis of NMDA 
receptor GluN1, GluN2, and GluN3 
ligand-binding domains reveals 
subtype-specific characteristics. 
Structure [Internet]. 2013 Oct 8 [cited 
2021 Aug 21];21(10):1788-99. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/23972471/
[8] SS W, S K. Glutamate, glutamate 
receptors, and downstream signaling 
pathways. Int J Biol Sci [Internet]. 2013 
Sep 22 [cited 2021 Aug 21];9(9):948-59. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/24155668/
[9] MY M, DA R, DM K. Activation of 
AMPA, kainate, and metabotropic 
receptors at hippocampal mossy fiber 
synapses: role of glutamate diffusion. 
Neuron [Internet]. 1998 [cited 2021 Aug 
21];21(3):561-70. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/9768842/
[10] Egebjerg J, Heinemann SF. Ca2+ 
permeability of unedited and edited 
versions of the kainate selective 
glutamate receptor GluR6. Proc Natl 
Acad Sci U S A [Internet]. 1993 Jan 15 
[cited 2021 Aug 21];90(2):755. Available 
from: /pmc/articles/
PMC45744/?report=abstract
[11] L VDB, W V, H K, E VH, W R. 
Ca(2+)-permeable AMPA receptors and 
selective vulnerability of motor 
neurons. J Neurol Sci [Internet]. 2000 
Nov 1 [cited 2021 Aug 21];180(1-2): 
29-34. Available from: https://pubmed.
ncbi.nlm.nih.gov/11090861/
[12] Rajakulendran S, Hanna MG. The 
Role of Calcium Channels in Epilepsy. 
Cold Spring Harb Perspect Med 
[Internet]. 2016 Jan 1 [cited 2021 Aug 
21];6(1). Available from: /pmc/articles/
PMC4691803/
[13] HF B. Glutamate, GABA and 
epilepsy. Prog Neurobiol [Internet]. 
1995 [cited 2021 Aug 21];47(6):477-511. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/8787032/
[14] Traynelis SF, Wollmuth LP, 
McBain CJ, Menniti FS, Vance KM, 
Ogden KK, et al. Glutamate Receptor 
Ion Channels: Structure, Regulation, 
and Function. Pharmacol Rev 
[Internet]. 2010 Sep [cited 2021 Aug 






[15] Catterall WA. Voltage-Gated 
Calcium Channels. Cold Spring Harb 
Perspect Biol [Internet]. 2011 [cited 
2021 Sep 19];3(8):1-23. Available from: /
pmc/articles/PMC3140680/
[16] Van Loo KMJ, Schaub C, Pitsch J, 
Kulbida R, Opitz T, Ekstein D, et al. Zinc 
regulates a key transcriptional pathway 
for epileptogenesis via metal-regulatory 
transcription factor 1. Nat Commun 
[Internet]. 2015 Oct 26 [cited 2021 Jun 
12];6. Available from: https://pubmed.
ncbi.nlm.nih.gov/26498180/
[17] Dezsi G, Ozturk E, Stanic D, 
Powell KL, Blumenfeld H, O’Brien TJ, et 
al. Ethosuximide reduces epileptogenesis 
and behavioral comorbidity in the 
GAERS model of genetic generalized 
epilepsy. Epilepsia [Internet]. 2013 Apr 
[cited 2021 Jun 12];54(4):635-43. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/23464801/
[18] Catterall WA, Kalume F, Oakley JC. 
NaV1.1 channels and epilepsy. Vol. 588, 
Journal of Physiology. 2010. p. 1849-59.
[19] Bondy SC. Intracellular calcium and 
neurotoxic events. Neurotoxicol Teratol. 
1989 Nov 1;11(6):527-531.
[20] Rowley S, Patel M. Mitochondrial 
involvement and oxidative stress in 
temporal lobe epilepsy [Internet]. Vol. 
62, Free Radical Biology and Medicine. 
Elsevier Inc.; 2013 [cited 2020 May 12]. 
p. 121-31. Available from: http://www.
ncbi.nlm.nih.gov/pubmed/23411150
[21] Waldbaum S, Patel M. 
Mitochondria, oxidative stress, and 
temporal lobe epilepsy. Vol. 88, Epilepsy 
Research. 2010. p. 23-45.
[22] Zhu LJ, Chen Z, Zhang LS, Xu SJ, 
Xu AJ, Luo JH. Spatiotemporal changes 
of the N-methyl-D-aspartate receptor 
subunit levels in rats with 
pentylenetetrazole-induced seizures. 
Neurosci Lett [Internet]. 2004 Feb 6 
[cited 2021 Jun 6];356(1):53-6. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/14746900/
[23] Rosiles A, Rubio C, Trejo C, 
Gutierrez J, Hernández L, Paz C. 
Commentary: Participation of Sox-1 
Expression and Signaling of β-Catenin 
in the Pathophysiology of Generalized 
Seizures in Cerebellum of Rat. CNS 
Neurol Disord - Drug Targets. 
2016;15(1):3-6.
[24] XT L, W M, XB W, Z L, JW Y, Y H, 
et al. Notoginsenoside R1 Promotes the 
Growth of Neonatal Rat Cortical 
Neurons via the Wnt/β-catenin 
Signaling Pathway. CNS Neurol Disord 
Drug Targets [Internet]. 2018 Jul 11 
[cited 2021 Sep 19];17(7):547-56. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/29992896/
[25] Rubio C, Rosiles-Abonce A, 
Trejo-Solís C, Rubio-Osornio M, 
Mendoza C, Custodio V, et al. Increase 
signaling of Wnt/β-catenin pathway and 
presence of apoptosis in cerebellum of 
kindled rats. CNS Neurol Disord - Drug 
Targets. 2017;16(7).
[26] Rubio C, Luna R, Rosiles A, 
Rubio-Osornio M. Caloric Restriction 
and Ketogenic Diet Therapy for 
Epilepsy: A Molecular Approach 
Involving Wnt Pathway and KATP 
Channels. Front Neurol. 
2020;11(November):1-17.
[27] Jett DA. Chemical toxins that cause 
seizures. Neurotoxicology [Internet]. 
2012 Dec [cited 2021 Jun 12];33(6): 
1473-5. Available from: https://pubmed.
ncbi.nlm.nih.gov/23085523/
[28] Jett DA. Neurotoxic Pesticides and 
Neurologic Effects [Internet]. Vol. 29, 
Neurologic Clinics. Neurol Clin; 2011 
[cited 2021 Jun 12]. p. 667-77. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/21803217/
[29] Assessment UENC for E. Handbook 
of neurotoxicology. 2009 Mar 15;
Neurotoxicity - New Advances
14
[30] Sutter R, Rüegg S, Tschudin- 
Sutter S. Seizures as adverse events of 
antibiotic drugs : A systematic review 
[Internet]. Vol. 85, Neurology. 
Lippincott Williams and Wilkins; 2015 
[cited 2021 Jun 12]. p. 1332-41. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/26400582/
[31] Hitchings AW. Drugs that lower 
the seizure threshold. Adverse Drug 
React Bull. 2016 Jun 
1;298(1):1151-1154.
[32] Kanner AM. Most antidepressant 
drugs are safe for patients with epilepsy 
at therapeutic doses: A review of the 
evidence [Internet]. Vol. 61, Epilepsy 
and Behavior. Academic Press Inc.; 2016 
[cited 2021 Jun 12]. p. 282-6. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/27236241/
[33] Johannessen Landmark C, Henning O, 
Johannessen SI. Proconvulsant effects of 
antidepressants — What is the current 
evidence? [Internet]. Vol. 61, Epilepsy and 
Behavior. Academic Press Inc.; 2016 [cited 
2021 Jun 12]. p. 287-91. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/26926001/
[34] Grill MF, Maganti RK. Neurotoxic 
effects associated with antibiotic use: 
Management considerations. Br J Clin 
Pharmacol [Internet]. 2011 Sep [cited 
2021 Jun 12];72(3):381-93. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/21501212/
[35] N K, K G, A A, PS C, M T. Valproic 
acid as an antiepileptic drug: Is there a 
clinical relevance for the epilepsy 
surgeon? Epilepsy Res [Internet]. 2016 
Nov 1 [cited 2021 Aug 21];127:191-4. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/27610748/
[36] Bourin M. Mechanism of Action of 
Valproic Acid and Its Derivatives. 2020 
[cited 2021 Aug 21]; Available from: 
www.symbiosisonlinepublishing.com
[37] M R, P M, R D, S S, VE R, A V, et al. 
Valproic Acid and Epilepsy: From 
Molecular Mechanisms to Clinical 
Evidences. Curr Neuropharmacol 
[Internet]. 2019 Dec 28 [cited 2021 Aug 
21];17(10):926-46. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/30592252/
[38] MM Z, HL L, LH S, XP C, J L, ZL Z. 
The pharmacogenomics of valproic acid. 
J Hum Genet [Internet]. 2017 Dec 1 
[cited 2021 Aug 21];62(12):1009-14. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/28878340/
[39] Y G-P, CF T, JK L, JS L, W S, AK B, 
et al. Valproic acid pathway: 
pharmacokinetics and 
pharmacodynamics. Pharmacogenet 
Genomics [Internet]. 2013 [cited 2021 
Aug 21];23(4):236-41. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/23407051/
[40] Diederich M, Chateauvieux S, 
Morceau F, Dicato M. Molecular and 
therapeutic potential and toxicity of 
valproic acid. J Biomed Biotechnol. 
2010;2010.
[41] RM N, MG N. Adverse drug 
reactions induced by valproic acid. Clin 
Biochem [Internet]. 2013 Oct [cited 
2021 Aug 21];46(15):1323-38. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/23792104/
[42] MD S. Valproic acid toxicity: 
overview and management. J Toxicol 
Clin Toxicol [Internet]. 2002 [cited 2021 
Aug 21];40(6):789-801. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/12475192/
[43] V G, AK M, M K, B S, P G, M K. 
Valproic acid induced acute liver injury 
resulting in hepatic encephalopathy- a 
case report and literature review. J 
community Hosp Intern Med Perspect 
[Internet]. 2018 Sep 3 [cited 2021 Aug 





[44] GM P. Clinical Pharmacology of 
Phenobarbital in Neonates: Effects, 
Metabolism and Pharmacokinetics. Curr 
Pediatr Rev [Internet]. 2016 Feb 1 [cited 
2021 Aug 21];12(1):48-54. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/26496779/
[45] N A-M, A S-R, S V, PA F. Neonatal 
phenobarbital exposure disrupts 
GABAergic synaptic maturation in rat 
CA1 neurons. Epilepsia [Internet]. 2018 
Feb 1 [cited 2021 Aug 21];59(2):333-44. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/29315524/
[46] Cherian, Thomas S V. Status 
epilepticus. Ann Indian Acad Neurol 
[Internet]. 2009 Jul 1 [cited 2021 Aug 





[47] Phenobarbital: biopharmacology - 
PubMed [Internet]. [cited 2021 Aug 21]. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/6990708/
[48] S K, RB S, JT D. Drug absorption. V. 
Influence of food on oral absorption of 
phenobarbital in rats. J Pharm Sci 
[Internet]. 1971 [cited 2021 Aug 
21];60(11):1639-41. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/5133911/
[49] J G, M G, SR B. Carbamazepine-
related antiepileptic drugs for the 
treatment of epilepsy - a comparative 
review. Expert Opin Pharmacother 
[Internet]. 2016 May 2 [cited 2021 Aug 
21];17(7):885-8. Available from: https://
pubmed.ncbi.nlm.nih.gov/26999402/
[50] Carbamazepine Toxicity - PubMed 
[Internet]. [cited 2021 Aug 21]. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/29939629/
[51] L B. Clinical pharmacokinetics of 
carbamazepine. Clin Pharmacokinet 
[Internet]. 1978 [cited 2021 Aug 
21];3(2):128-43. Available from: https://
pubmed.ncbi.nlm.nih.gov/346287/
[52] Gupta M, Tripp J. Phenytoin. Encycl 
Toxicol Third Ed [Internet]. 2021 Jul 25 
[cited 2021 Aug 21];895-7. Available 
from: https://www.ncbi.nlm.nih.gov/
books/NBK551520/
[53] Y Y, ME S, JH P. Phenytoin: 
mechanisms of its anticonvulsant 
action. Ann Neurol [Internet]. 1986 
[cited 2021 Aug 21];20(2):171-84. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/2428283/
[54] Bochner F, Hooper WD, Tyrer JH, 
Eadie MJ. Effect of dosage increments 
on blood phenytoin concentrations. J 
Neurol Neurosurg Psychiatry [Internet]. 
1972 [cited 2021 Aug 21];35(6): 
873. Available from: /pmc/articles/
PMC494195/?report=abstract
[55] J P, Q W, E N, K K. Phenytoin - An 
anti-seizure drug: Overview of its 
chemistry, pharmacology and 
toxicology. Food Chem Toxicol 
[Internet]. 2020 Aug 1 [cited 2021 Aug 
21];142. Available from: https://
pubmed.ncbi.nlm.nih.gov/32376339/
[56] A I, BZ H. Phenytoin Toxicity. 2021 
[cited 2021 Aug 21]; Available from: 
https://pubmed.ncbi.nlm.nih.
gov/29494051/
[57] JM M, R M, O D. Phenytoin 
intoxication. South Med J [Internet]. 
1991 [cited 2021 Aug 21];84(10): 
1199-204. Available from: https://
pubmed.ncbi.nlm.nih.gov/1925719/
[58] Soderstrom J, Murray L, Little M, 
Daly FFS. Toxicology case of the month: 
carbamazepine overdose. Emerg Med J 
[Internet]. 2006 Nov [cited 2021 Aug 
21];23(11):869. Available from: /pmc/
articles/PMC2464388/
[59] Lamotrigine. An update of its 
pharmacology and therapeutic use in 
Neurotoxicity - New Advances
16
epilepsy - PubMed [Internet]. [cited 
2021 Aug 21]. Available from: https://
pubmed.ncbi.nlm.nih.gov/8536554/
[60] Betchel NT, Fariba K, Saadabadi A. 
Lamotrigine. Essence Analg Analg 
[Internet]. 2021 Aug 6 [cited 2021 Aug 
21];306-9. Available from: https://www.
ncbi.nlm.nih.gov/books/NBK470442/
[61] G P. Risks associated with 
lamotrigine prescription: a review and 
personal observations. Australas 
Psychiatry [Internet]. 2018 Dec 1 [cited 
2021 Aug 21];26(6):640-2. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/29480028/
[62] Lamotrigine | CAS#84057-84-1 | 
Anticonvulsant | MedKoo [Internet]. 
[cited 2021 Aug 21]. Available from: 
https://www.medkoo.com/
products/8283
[63] MM K, NA H. Oxcarbazepine, an 
antiepileptic agent. Clin Ther [Internet]. 
2001 [cited 2021 Aug 21];23(5): 
680-700. Available from: https://
pubmed.ncbi.nlm.nih.gov/11394728/
[64] S S. Oxcarbazepine: a review. 
Seizure [Internet]. 2000 [cited 2021 
Aug 21];9(2):75-9. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/10845729/
[65] EJ P, C S, M W-C, DJ M, HM D, W C, 
et al. Clinical Pharmacogenetics 
Implementation Consortium Guideline 
for HLA Genotype and Use of 
Carbamazepine and Oxcarbazepine: 2017 
Update. Clin Pharmacol Ther [Internet]. 
2018 Apr 1 [cited 2021 Aug 
21];103(4):574-81. Available from: https://
pubmed.ncbi.nlm.nih.gov/29392710/
[66] Hu X, Fu X, Jiang A, Yang X, 
Fang X, Gong G, et al. Multiomic 
analysis of mice epilepsy models suggest 
that MIR-21a expression modulates 
mRNA and protein levels related to 
seizure deterioration. Genet Res 
(Camb). 2015 Dec 22;97.
[67] JJ A. Use of antiepileptic drugs in 
hepatic and renal disease. Handb Clin 
Neurol [Internet]. 2014 [cited 2021 
Aug 21];119:417-32. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/24365310/
[68] H S, M G, J O. Ethosuximide 
induced macroglossia and 
oropharyngeal edema. Int J Pediatr 
Otorhinolaryngol [Internet]. 2021 Jan 1 
[cited 2021 Aug 21];140. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/33218689/
[69] T W, P C, J C. Ethosuximide-
induced drug reaction with eosinophilia 
and systemic symptoms with 
mediastinal lymphadenopathy. Pediatr 
Dermatol [Internet]. 2019 Jul 1 [cited 
2021 Aug 21];36(4):e99-101. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/31132165/
[70] S M, CC L, M U, S E. Pregabalin and 
gabapentin for pain. BMJ [Internet]. 
2020 Apr 28 [cited 2021 Aug 21];369. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/32345589/
[71] KE E, JR C, AM P, L O, KE H. 
Reports of gabapentin and pregabalin 
abuse, misuse, dependence, or overdose: 
An analysis of the Food And Drug 
Administration Adverse Events 
Reporting System (FAERS). Res Social 
Adm Pharm [Internet]. 2019 Aug 1 
[cited 2021 Aug 21];15(8):953-8. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/31303196/
[72] Bonifacio SL, VanMeurs K. 
Neuroprotective Therapies in Infants. 
Infect Dis Pharmacol. 2019 Jan 
1;227-241.
[73] JP R, ALF C. Topiramate-Associated 
Movement Disorder: Case Series and 
Literature Review. Clin Neuropharmacol 
[Internet]. 2020 Jul 1 [cited 2021 Aug 






[74] Rubio C, Rubio-Osornio M, 
Retana-Marquez S, Lopez M, 
Custodio V, Paz C. In Vivo Experimental 
Models of Epilepsy. Cent Nerv Syst 
Agents Med Chem [Internet]. 2010 Dec 





[75] Jasper HH. E |An. O. Basic 
Mechanisms of the Epilepsies. Little, 
Brown and Company, 34 Beacon Street, 
Boston, Massachusetts 02106; 1969.
[76] Ribak CE, Harris AB, Vaughn JE, 
Roberts E. Inhibitory, GABAergic nerve 
terminals decrease at sites of focal 
epilepsy. Science (80- ) [Internet]. 1979 
[cited 2021 Jun 6];205(4402):211-4. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/109922/
[77] JS L, V U, LL D, JA F, BJ H. Efficacy 
of standard anticonvulsants in monkey 
model with spontaneous motor seizures. 
Epilepsia [Internet]. 1975 [cited 2021 
Aug 21];16(2):301-17. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/1171007/
[78] Borbély S, Dobó E, Czégé D, 
Molnár E, Bakos M, Szucs B, et al. 
Modification of ionotropic glutamate 
receptor-mediated processes in the rat 
hippocampus following repeated, brief 
seizures. Neuroscience [Internet]. 2009 
Mar 3 [cited 2021 Jun 6];159(1):358-68. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/19154779/
[79] Craig CR, Colasanti BK. GABA 
receptors, lipids, and gangliosides in 
cobalt epileptic focus. [Internet]. Vol. 
44, Advances in neurology. 1986 [cited 
2021 Jun 6]. p. 379-91. Available from: 
https://europepmc.org/article/
med/3010678
[80] Tsuda T, Sugaya A, Ohguchi H, 
Kishida N, Sugaya E. Protective effects 
of peony root extract and its 
components on neuron damage in the 
hippocampus induced by the cobalt 
focus epilepsy model. Exp Neurol 
[Internet]. 1997 [cited 2021 Jun 
6];146(2):518-25. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/9270063/
[81] Kapur J, Macdonald RL. Rapid 
Seizure-Induced Reduction of 
Benzodiazepine and Zn 2 Sensitivity of 
Hippocampal Dentate Granule Cell 
GABA A Receptors. 1997.
[82] Sørensen J, Slomianka L, 
Christensen J, Zimmer J. Zinc-
containing telencephalic connections to 
the rat striatum: a combined Fluoro-
Gold tracing and histochemical study. 
Exp Brain Res [Internet]. 1990 Feb 1 
[cited 2021 Jun 6];105(3):370-82. 
Available from: http://link.springer.
com/10.1007/BF00233037
[83] Furtinger S, Bettler B, Sperk G. 
Altered expression of GABAB receptors 
in the hippocampus after kainic-acid-
induced seizures in rats. Mol Brain Res 
[Internet]. 2003 May 12 [cited 2021 Jun 
6];113(1-2):107-15. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/12750012/
[84] Vezzani A, Sperk G, Colmers WF. 
Neuropeptide Y: Emerging evidence for 
a functional role in seizure modulation 
[Internet]. Vol. 22, Trends in 
Neurosciences. Elsevier Ltd; 1999 [cited 
2021 Jun 6]. p. 25-30. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/10088996/
[85] Sperk G. Kainic acid seizures in the 
rat [Internet]. Vol. 42, Progress in 
Neurobiology. Prog Neurobiol; 1994 
[cited 2021 Jun 6]. p. 1-32. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/7480784/
[86] Tian FF, Zeng C, Guo TH, Chen Y, 
Chen JM, Ma YF, et al. Mossy fiber 
sprouting, hippocampal damage and 
spontaneous recurrent seizures in 
Neurotoxicity - New Advances
18
pentylenetetrazole kindling rat model. 
Acta Neurol Belg [Internet]. 2009 Dec 1 
[cited 2021 Jun 6];109(4):298-304. 
Available from: https://europepmc.org/
article/med/20120210
[87] Li X, Kuang H, Jiang N, Hu Y. 
Involvement of Scn1b and Kcna1 ion 
channels in audiogenic seizures and 
PTZ-induced epilepsy. Epilepsy Res 
[Internet]. 2005 [cited 2021 Jun 6];66(1-
3):155-63. Available from: https://
pubmed.ncbi.nlm.nih.gov/16157473/
[88] Clark CR. Comparative 
Anticonvulsant Activity and 
Neurotoxicity of 4-Amino-N-(2,6-
dimethylphenyl) benzamide and 
Prototype Antiepileptic Drugs in Mice 
and Rats. Epilepsia [Internet]. 1988 Apr 




[89] RA U, AY C, EA S. Effects of gamma-
aminobutyric acid (GABA) receptor 
agonists on the neurotoxicity and 
anticonvulsant activity of barbiturates in 
mice. J Pharmacol Exp Ther [Internet]. 
1986 [cited 2021 Aug 21];237(2):468-72. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/3009786/
[90] Bertram EH, Lothman EW, 
Lenn NJ. The hippocampus in 
experimental chronic epilepsy: A 
morphometric analysis. Ann Neurol 
[Internet]. 1990 [cited 2021 Jun 
6];27(1):43-8. Available from: https://
pubmed.ncbi.nlm.nih.gov/2301927/
[91] Nevander G, Ingvar M, Auer R, 
Siesjö BK. Status epilepticus in well–
oxygenated rats causes neuronal 
necrosis. Ann Neurol [Internet]. 1985 
[cited 2021 Jun 6];18(3):281-90. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/4051457/
[92] Szot P, Weinshenker D, White SS, 
Robbins CA, Rust NC, 
Schwartzkroin PA, et al. 
Norepinephrine-deficient mice have 
increased susceptibility to seizure- 
inducing stimuli. J Neurosci [Internet]. 
1999 Dec 15 [cited 2021 Jun 
6];19(24):10985-92. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/10594079/
[93] Avoli M. Feline generalized 
penicillin epilepsy. Ital J Neurol Sci 
[Internet]. 1995 Mar [cited 2021 Jun 
6];16(1-2):79-82. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/7642356/
[94] Akdogan I, Adiguzel E, Yilmaz I, 
Ozdemir MB, Sahiner M, Tufan AC. 
Penicillin-induced epilepsy model in 
rats: Dose-dependant effect on 
hippocampal volume and neuron 
number. Brain Res Bull [Internet]. 2008 
Oct 22 [cited 2021 Jun 6];77(4):172-7. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/18762233/
[95] Ni H, Jiang Y wu, Tao L yuang, Cen 
J nong, Wu X ru. Effects of penicillin-
induced developmental epilepticus on 
hippocampal regenerative sprouting, 
related gene expression and cognitive 
deficits in rats. Toxicol Lett [Internet]. 
2009 Jul 24 [cited 2021 Jun 
6];188(2):161-6. Available from: https://
pubmed.ncbi.nlm.nih.gov/19446251/
[96] Söderfeldt B, Kalimo H, Olsson Y, 
Siesjö B. Pathogenesis of brain lesions 
caused by experimental epilepsy - 
Light- and electron-microscopic 
changes in the rat cerebral cortex 
following bicuculline-induced status 
epilepticus. Acta Neuropathol 
[Internet]. 1981 Sep 1 [cited 2021 Jun 
6];54(3):219-31. Available from: 
https://europepmc.org/article/
med/7257731
[97] Seutin V, Johnson SW. Recent 
advances in the pharmacology of 
quaternary salts of bicuculline 
[Internet]. Vol. 20, Trends in 
Pharmacological Sciences. Elsevier Ltd; 






[98] Mitchell J, Gatherer M, 
Sundstrom LE. Aberrant Timm-stained 
fibres in the dentate gyrus following 
tetanus toxin-induced seizures in the 
rat. Neuropathol Appl Neurobiol 
[Internet]. 1996 Apr 1 [cited 2021 Jun 
6];22(2):129-35. Available from: https://
onlinelibrary.wiley.com/doi/
full/10.1111/j.1365-2990.1996.tb00856.x
[99] Jordan SJ, Jefferys JGR. Sustained 
and selective block of IPSPs in brain 
slices from rats made epileptic by 
intrahippocampal tetanus toxin. 
Epilepsy Res. 1992 Apr 1;11(2):119-129.
[100] Cavalheiro EA, Leite JP, 
Bortolotto ZA, Turski WA, 
Ikonomidou C, Turski L. Long-Term 
Effects of Pilocarpine in Rats: Structural 
Damage of the Brain Triggers Kindling 
and Spontaneous I Recurrent Seizures. 
Epilepsia [Internet]. 1991 [cited 2021 
Jun 6];32(6):778-82. Available from: 
https://pubmed.ncbi.nlm.nih.
gov/1743148/
[101] Gibbs JW, Shumate MD, 
Coulter DA. Differential epilepsy-
associated alterations in postsynaptic 
GABA(A) receptor function in dentate 
granule and CA1 neurons. J 
Neurophysiol [Internet]. 1997 [cited 
2021 Jun 6];77(4):1924-38. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/9114245/
[102] Fernandes MJS, 
Naffah-Mazzacoratti MG, 
Cavalheiro EA. Na+K+ ATPase activity 
in the rat hippocampus: A study in the 
pilocarpine model of epilepsy. 
Neurochem Int [Internet]. 1996 [cited 
2021 Jun 6];28(5-6):497-500. Available 
from: https://pubmed.ncbi.nlm.nih.
gov/8792330/
[103] Scorza CA, Garrido YDC, 
Arida RM, Amado D, Cavalheiro EA, 
Naffah-Mazzacoratti MDG. Levels of 
the synaptic protein X11 alpha/mint1 
are increased in hippocampus of rats 
with epilepsy. Epilepsy Res [Internet]. 
2003 [cited 2021 Jun 6];57(1):49-57. 
Available from: https://pubmed.ncbi.
nlm.nih.gov/14706732/
